| 货号 | MAB3688-SP |
| 别名 | D6Bwg0781e; Img; LIG1; LIG-1 | 全称 | Leucine-rich Repeats and Immunoglobulin-like Domains 1 |
| 反应种属 | Mouse |
| 应用 | Blockade of Receptor-ligand Interaction |
| 目标/特异性 | Detects mouse LRIG1 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human LRIG3 is observed. |
| 使用方法 | Blockade of Receptor-ligand Interaction: In a functional ELISA, 0.02-0.1 μg/mL of this antibody will block 50% of the binding of 250 ng/mL of Recombinant Human ErbB4/Her4 Fc Chimera (Catalog # 1131-ER) to immobilized Recombinant Mouse LRIG1 (Catalog # 3688-LR) coated at 2.5 μg/mL (100 µL/well). At 5 μg/mL, this antibody will block >90% of the binding. |
| 来源 | Monoclonal Rat IgG2A Clone # 440710 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 26018 (Human); 16206 (Mouse); 312574 (Rat) |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant mouse LRIG1 Ala37-Thr794 Accession # P70193 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Mouse |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | LRIG1 (formerly LIG-1) is one of three mammalian LRR (leucine-rich repeat) and Ig-like domain-containing type I transmembrane glycoproteins that share 45‑50% amino acid (aa) identity (1, 2). All contain fifteen LRRs flanked by cysteine-rich regions and three C-type Ig-like domains within their extracellular domains (ECD) (1, 2). LRIG1 shows the highest expression in liver, brain, stomach, small intestine and skeletal muscle (2). Expression is prominent in certain epithelia and subsets of glial cells (1, 2). Within the cell, LRIG1 is expressed in the perinuclear region as well as on the surface. Mouse LRIG1 is synthesized with a 37 aa signal sequence, a 759 aa ECD, a 21 aa transmembrane sequence and a 295 aa intracellular region that binds the ubiquitin ligase, c-Cbl (3). LRIG1 binds the EGF receptor (ErbB1) or neuregulin receptors (ErbB2, 3 and 4) via either its LRR or Ig-like domains and promotes ubiquitination, internalization and destruction of these receptors (3, 4). Since LRIG1 modulates growth factor receptor expression, there is an inverse relationship between LRIG1 expression and proliferative capacity. Genetic disruption of mouse LRIG1 results in a psoriasis-like epidermal hyperplasia on the tail and facial area, which is consistent with downregulation of LRIG1 in human psoriatic lesions (5). High ratios of EGF R to LRIG1 in human renal cell carcinomas correlate with poor survival (6). In skin squamous cell carcinomas, high LRIG1 expression correlates with a more differentiated state and a survival benefit (7). Mouse LRIG1 ECD shows 90%, 93%, 90% and 87% aa identity with human, rat, bovine and canine LRIG1 ECD, respectively. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|